Newsletter | April 6, 2026

04.06.26 -- February 2026 — CDMO Opportunities And Threats Report

SPONSOR

Webinar: OneTeam™: Setting A New Standard For Biotech Program Visibility

Outsourced gene therapy shouldn’t mean scattered systems and siloed updates. In this Andelyn webinar, discover how the OneTeam™ approach replaces “black box” confusion with clear, connected collaboration. Learn how unified data dashboards, streamlined governance, and shared digital tools reduce risk, improve visibility, and empower sponsors and CDMOs to move faster, communicate better, and confidently manage the entire product lifecycle seamlessly. Click here to learn more.

FOCUS ON OUTSOURCING

February 2026 — CDMO Opportunities And Threats Report

Each month, Outsourced Pharma with GlobalData presents its “Contract Manufacturing: Opportunities and Threats (CMOT) Report.” It identifies CDMOs that may be impacted by key events affecting their clients, such as company acquisitions, product acquisitions and licenses, product approvals and terminations, and FDA rejections.

Consistency You Can Trust In Animal‑Free Raw Materials

Animal‑free raw materials ensure reliable bioprocessing through stable molecular weight profiles, consistent mineral levels, and controlled manufacturing for dependable lot‑to‑lot performance.

New Standards For Elastomeric Components In Sterile Packaging

USP’s new elastomeric packaging standards shift testing to full system‑level evaluation, strengthen integrity and usability expectations, and place compliance responsibility on drug developers.

CRISPR Gene Editing, CDMOs, And The Art Of "Just Right"

Learn how finding the right combination of capabilities and expertise in a CDMO can set you up for success and keep your innovative project on time and within budget.

Pioneering Affordable CAR-T Cell Therapies In India

CAR-T cell therapy is poised to transform cancer care in India, with new initiatives aiming to make this breakthrough treatment both clinically feasible and financially accessible.

Lentiviral Vectors: The Key To Cell And Gene Therapy Success

Lentiviral vector manufacturing is complex and highly regulated, which is why a specialized CDMO is required to ensure safe, scalable, and compliant production from early development to commercialization.

The 14 Month Race: How Partnership And Capability Developed A Gene Therapy

Hear how one family, driven by urgency, partnered with AAV experts to develop a treatment for their daughter’s ultra-rare neurodegenerative disorder, NEDAMSS, in just 14 months.

OUTSOURCING SOLUTIONS

Gene Therapy, Oncolytic Viruses, Viral Vaccines CDMO Services - FUJIFILM Biotechnologies

Accelerating Cell Therapy Innovations From Lab To Market - Kincell Bio

LEG14-Mediated TCR Knock-In For T-Cell Engineering - ElevateBio

Platform Optimized For Scale-up And Transfer Of CAR-T - Landmark Bio

The Strategic Partner For Temperature Control - Cryoport Systems

Connect With Cell & Gene: